Age (years) | | |
Mean (range) | 73.82 (59–90) | |
Heigth (m) | | |
Mean (range) | 1.71 (1.58–1.95) | |
Weight (kg) | | |
Mean (range) | 78.60 (59–120) | |
BMI | | |
Mean (range) | 26.75 (19.57–39.18) | |
Gleason score | | |
Mean (range) | 6.3 (5–10) | |
5 | 1 | 0.79 |
6 | 3 | 2.36 |
7 | 38 | 29.92 |
8 | 30 | 23.62 |
9 | 28 | 22.04 |
10 | 2 | 1.59 |
Unknown | 25 | 19.68 |
ECOG Performance status | | |
Mean (range) | 0.86 (0–3) | |
0 | 39 | 30.7 |
1 | 68 | 53.54 |
2–3 | 20 | 15.75 |
Extent of skeletal disease | | |
< 6 metastases | 18 | 14.17 |
6–20 metastases | 46 | 36.22 |
> 20 metastases | 63 | 49.61 |
No. of previous systemic treatments after | | |
castration resistance (Docetaxel, Cabazitaxel, | | |
Abiraterone, Enzalutamide) | | |
0 | 32 | 25.19 |
1 | 42 | 33.07 |
2 | 32 | 25.19 |
≥ 3 | 21 | 16.53 |
No. of therapy’s cycles administered | | |
Mean (range) | 5.56 (2–6) | |
2 | 3 | 2.36 |
3 | 3 | 2.36 |
4 | 10 | 7.87 |
5 | 14 | 11.02 |
6 | 97 | 76.38 |
No. of systemic treatments after Radium223 | | |
Docetaxel | 11 | 8.6 |
Cabazitaxel | 0 | 0 |
Abiraterone | 2 | 1.5 |
Enzalutamide | 6 | 4.7 |
Baseline Hb | | |
Median (range) | 12.14 (7.5–15) | |
< 12 g/dl | 54 | 42.51 |
≥ 12 g/dl | 73 | 57.48 |
Baseline tALP* | | |
Median (range) | 300 (34–1750) | |
< 226 U/l | 79 | 62.2 |
≥ 226 U/l | 48 | 87.8 |
Baseline PLT (103/mm3) | | |
Median (range) | 249 (74–763) | |
Baseline PSA | | |
< 20 ng/ml | 42 | 33.07 |
≥ 20 ng/ml | 85 | 66.92 |